Orelabrutinib manufacturers
- Orelabrutinib
-
- $83.00 / 1mg
-
2024-11-18
- CAS:1655504-04-3
- Min. Order:
- Purity: 99.44%
- Supply Ability: 10g
- Orelabrutinib
-
- $83.00 / 1mg
-
2024-11-18
- CAS:1655504-04-3
- Min. Order:
- Purity: 99.44%
- Supply Ability: 10g
- Orelabrutinib USP/EP/BP
-
- $1.10 / 1g
-
2021-07-06
- CAS:1655504-04-3
- Min. Order: 1g
- Purity: 99.9%
- Supply Ability: 100 Tons Min
|
| | Orelabrutinib Basic information |
| Product Name: | Orelabrutinib | | Synonyms: | :6-[1-(1-oxo-2-propen-1-yl)-4-piperidinyl]-2-(4-phenoxyphenyl)-3-Pyridinecarboxamide;Orelabrutinib;ICP-022;3-Pyridinecarboxamide, 6-[1-(1-oxo-2-propen-1-yl)-4-piperidinyl]-2-(4-phenoxyphenyl)-;Orelabrutinib USP/EP/BP;6-(1-Acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide;Malignancies,Btk,ICP 022,inhibit,antineoplastic,Inhibitor,chronic,small,Bruton tyrosine kinase,lymphocytic leukemia,cell,Orelabrutinib,ICP022;Orelabrutinib (ICP-022) | | CAS: | 1655504-04-3 | | MF: | C26H25N3O3 | | MW: | 427.49 | | EINECS: | | | Product Categories: | | | Mol File: | 1655504-04-3.mol |  |
| | Orelabrutinib Chemical Properties |
| Boiling point | 646.3±55.0 °C(Predicted) | | density | 1.213±0.06 g/cm3(Predicted) | | form | Solid | | pka | 14.80±0.50(Predicted) | | color | White to off-white |
| | Orelabrutinib Usage And Synthesis |
| Description | Orelabrutinib is a small molecule inhibitor of Bruton's tyrosine kinase with potential antineoplastic activity. | | Description |
In December 2020, orelabrutinib was approved by the China National Medical Products Administration for treating patients with relapsed/refractory MCL, CLL, and SLL. This compound is also being evaluated for the treatment of multiple sclerosis. Orelabrutinib, which has a unique pyridylcarboxamide hinge binder, showed an IC50 value of 1.6 nM in the BTK enzymatic assay. When tested against a panel of 456 kinases at 1 μM, orelabrutinib only inhibited BTK (>90%), while ibrutinib also targeted several other kinases, including EGFR, TEC, and BMX. Orelabrutinib has a favorable half-life of 4 h in healthy volunteers.1,2 It is administered orally at a daily dose of 150 mg.
| | Uses | Orelabrutinib has been previously approved to treat patients with relapsed or refractory (R/R) mantle cell lymphoma and R/R chronic lymphocytic leukemia/small lymphocytic lymphoma. | | Brand name | InnobrukaTM
| | General Description |
Class: non-receptor tyrosine kinase
Treatment: CLL, SLL, MCL
Elimination half-life = 4 h
Protein binding = not reported
| | Biological Activity | Orelabrutinib (ICP-022) is a potent, orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK). | | Mechanism of action | Upon administration, orelabrutinib binds to and inhibits the activity of BTK. This prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK. | | target |
| | Orelabrutinib Preparation Products And Raw materials |
|
|
Tag:Orelabrutinib(1655504-04-3)
Related Product Information
|
|
Rituximab
Lenalidomide
|
According to the laws, regulations and policies related to "patent products", the sale of this product is prohibited!
ChemicalBook prompt
The patent owner or licensee of the product has not released any relevant information for the time being.
|